AzTrials
AzTrials

ScreeningPhase 1NCT07677917

Preoperative Nebulized Dexmedetomidine Versus Nebulized Magnesium Sulphate in Reducing Emergence Agitation in FESS

A Phase 1 study testing Dexmedetomidine and Magnesium sulfate in people with Screening, run by Ain Shams University at 1 site in Egypt.

Enrolling by invitation

Enrolling by invitation. The study team selects and invites participants, usually from an existing group of patients.

Sites and contacts
Official record

Search all trials

Trial summary

Emergence agitation after sinus surgery is a common postoperative complication characterized by confusion, disorientation, and potentially violent behavior as a patient wakes from general anesthesia.This study compare the effect of nebulized dexmedetomidine versus nebulized magnesium sulphate in reducing emergence… Read more about this study

Who is it for?
Ages 21 to 50 yearsHealthy volunteers can take part
Conditions the study is for
Screening
What is being tested?
Dexmedetomidine and Magnesium sulfate
Could I receive a placebo?
No, everyone receives an active treatment
How many people
50 participants
Where
1 siteEgypt
Study dates
22 Jan 2026to 22 Jan 2027
Phase
Phase 1

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 to 50 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Adult patients between 21 and 50 years of age undergoing elective functional endoscopic sinus surgery.
  • American Society of Anesthesiologists physical status classification (ASA) I and II.

Who cannot join

  • Patient's refusal.
  • Complicated sinus surgery.
  • History of allergy to any of the study drugs.
  • Baseline HR≤60 beat/min.
  • Baseline mean arterial pressure (MAP)≤70 mmHg.
  • Psychiatric illness.
  • Cerebrovascular insufficiency.
  • Pregnancy.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Egypt1 site
  • Ain Shams University Hospitals

    Cairo

Other trials in Egypt

About this study

Official title: Preoperative Nebulized Dexmedetomidine Versus Nebulized Magnesium Sulphate in Reducing Emergence Agitation in Adult Undergoing Functional Endoscopic Sinus Surgery.

Emergence agitation after sinus surgery is a common postoperative complication characterized by confusion, disorientation, and potentially violent behavior as a patient wakes from general anesthesia.This study compare the effect of nebulized dexmedetomidine versus nebulized magnesium sulphate in reducing emergence agitation in adult undergoing functional endoscopic sinus surgery.

This study aims to compare preoperative nebulized dexmedetomidine and nebulized magnesium sulphate in reducing emergence agitation in adult undergoing functional endoscopic sinus surgery.

Read the detailed description

Type of Study: Prospective, randomized, double-blind, comparative clinical study.

Study Setting: Ain Shams University hospitals, Cairo, Egypt. Study Period: 6-12 months. Study Population: Adult patients scheduled for elective functional endoscopic sinus surgery.

Sampling Method: Random sampling Sample Size Based on the results of Ahmed et al 2022, with the mean VAS in patients treated with magnesium sulphate 7.2 ± 1.9 while the mean in Dexmedetomedine group 2.7 ± 0.9 Alpha error 5%,power of study 80% the required sample size is 50 patients, 25 patients in each group. The program for sample size calculation is STATA 10.

Ethical Considerations:

The study protocol will receive ethical approval from the Research Ethical Committee, Faculty of Medicine Ain Shams University. Informed consent will be obtained from all participants before starting study.

Randomization and blinding:

Group allocation will be contained in sequentially numbered, sealed opaque envelopes, which will be opened by the primary investigator. the data analyzer will be blinded about the study group.

Study Procedures:

All patients will be assessed preoperatively by careful history taking, airway examination and systemic examination. Complete blood count (CBC), coagulation profile, liver and kidney function tests for all patients and electrocardiogram (ECG) for patients older than 40 years of age will be reviewed from patients medical records. A written informed consent will be signed by all patients before the surgery. All patients will be admitted after completing fasting hours for both solid food and clear fluids. Upon arrival to the operating room (OR), IV access of the size 20 gauge (G) will be inserted..

In the preoperative holding area, heart rate (HR), mean blood pressure (MBP) and peripheral blood oxygen saturation (SpO2) will be measured immediately before nebulization either dexmedetomidine or magnesium sulphate,.and regulary every 5 minutes until the end of nebulization.

Patients in Group D will be nebulized with 1 μg/kg nebulized dexmedetomidine completed to 3 ml using normal saline 30 min before operation and the patients in Group M will be nebulized with 250 mg nebulized magnesium sulfate completed to 3 ml using normal saline. The solution for nebulization will be administered by an anesthesiologist.

All patients will be monitored with a five-lead ECG, non-invasive blood pressure (NIBP) measurement and finger pulse oximetry. Baseline vital data (MAP, HR, and oxygen saturation (SO2)) will be recorded. HR and SO2 will be monitored continuosly and BP will be measured every 5 minutes (min) till the end of the surgery.

All patients will be premedicated with 0.03 mg/kg IV midazolam. Preoxygenation will be performed using 100% oxygen at a fresh gas flow (FGF) of 10 L/min via face mask for 3 minutes, followed by induction of general anesthesia.

Anesthesia will be induced with fentanyl 2 mcg/kg and propofol 2 mg/kg. Tracheal intubation will be facilitated by atracurium 0.5 mg/kg.

Both groups will be mechanically ventilated using volume control mode with tidal volume 7-10 ml/kg/min, positive end-expiratory pressure (PEEP) 5 cmH2O and oxygen-air mixture with fraction of inspired oxygen (FiO2) 50% and FGF of 3 L/min, and respiratory rate adjusted with target end-tidal carbon dioxide (ET CO2) 30-40 mmHg. 0.1 mg/kg IV atracurium will be given as needed to maintain muscle relaxation. 0.5 mcg/kg fentanyl will be given if HR or MAP increase ≥20% from their basal value. HR and MAP ≤20% of the basal value will be treated with needed doses of atropine and ephedrine, respectively. All patients will be extubated in the operating room and transferred to postanesthesia care unit (PACU).

Presence of emergence agitation will note in first 30 minutes in PACU using Aono's four-point scale scores after anesthesia.

Aono's four-point scale is used to assess post-anesthesia emergence agitation, where a score of 1 is calm, 2 is not calm but easily consoled, 3 is moderately agitated or restless, and 4 is combative, excited, or disoriented. Scores of 3 and 4 are generally considered to represent the presence of agitation and at this stage of agitation search for the cause and manage it .

In the postoperative ward, patients were also monitored for any drug-related side effects.

End point of study : After discharge of patients from PACU. The main researcher (Haidy Atef ) of the study will be the principal investigator responsible for the preparation and conduct of the study under supervision of the director (Prof. Dr. Moustafa Kamel) and co-directors(Prof. Dr. Hany Abdelfattah, Prof. Dr. Aktham Adel, Dr. Ahmed Saoudy). Each member of the team will ensure that the study is conducted according to the protocol approved in their meetings that will be arranged on regular basis. Results of the study and any complications that might occur during the study will be recorded and reported by the principal investigator and revised by the director and co-directors.

Statistical Analysis The collected data will be revised, coded and introduced to a PC using statistical package for social science (SPSS 23). Data will be presented as mean and standard deviation (±SD) for quantitative parametric data, median and range for quantitative non-parametric data and as numbers and percentage for qualitative data. Suitable analysis will be done according to the type of data obtained. P< 0.05 will be considered significant.

Conditions
Screening
Being tested
Dexmedetomidine, Magnesium sulfate

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • DexmedetomidineDrug

    Also called Precedex

    Patients in Group D will be nebulized with 1 μg/kg nebulized dexmedetomidine completed to 3 ml using normal saline 30 min before operation.The solution for nebulization will be administered by an anesthesiologist.

  • Magnesium sulfateDrug

    Also called magnesium sulphate

    Patients in Group M will be nebulized with 250 mg nebulized magnesium sulphate completed to 3 ml using normal saline 30 min before operation . The solution for nebulization will be administered by an anesthesiologist.

Study groups in NCT07677917
Study groupRoleWhat they receive
Group D (Dexmedetomedine)ExperimentalPatients in Group D will be nebulized with 1 μg/kg nebulized dexmedetomidine completed to 3 ml using normal saline 30 min before operation
Receives: Drug: Dexmedetomidine
Group M ( Magnesium Sulphate)ExperimentalGroup M will be nebulized with 250 mg nebulized magnesium sulfate completed to 3 ml using normal saline
Receives: Drug: Magnesium sulfate

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The primary endpoint will Visual Analogue Scale (VAS)score after anesthesia

    Pain will be assessed by VAS Score where 0 is no pain and 10 is the worst pain possible

    Measured: 30 minutes after operation in PACU

Secondary outcomes (3)
  1. The recovery time

    The time needed to discharge the patient from the PACU

    Measured: 30 minutes after operation in PACU

  2. Aono's four-point score will assessed as secondary endpoints.

    Aono's four-point scale is used to assess post-anesthesia emergence agitation, where a score of 1 is calm, 2 is not calm but easily consoled, 3 is moderately agitated or restless, and 4 is combative, excited, or disoriented.

    Measured: 30 minutes after operation in PACU

  3. The number, severity, and duration of agitation episode.

    The number, severity, and duration of agitation episode.

    Measured: 30 minutes after operation in PACU

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Jul 2026
  2. Study start22 Jan 2026
  3. Primary completion22 Jul 2026 (estimated)
  4. Study completion22 Jan 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Screening
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Investigator
Enrolment
50 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07677917
Sponsor's protocol ID
FMASU MD 05/2026
Status last verified
Apr 2026
First submitted
25 Apr 2026
Last updated
22 Jul 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: De-identified individual participant data underlying the study results will be made available upon reasonable request from qualified researches.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in